{
  "date": "2026-02-21",
  "items": [
    {
      "source": "pubmed",
      "pmid": "41719494",
      "doi": "10.1212/WNL.0000000000214703",
      "title": "Neuroimaging Biomarkers of Disease Progression and Cognitive Change in Patients With Retinal Vasculopathy With Cerebral Leukoencephalopathy.",
      "abstract": "A monogenic, age-related cerebral small vessel disease (cSVD), retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S), causes accelerated vascular dementia, vision loss, and premature death. Given knowledge is limited regarding its pathophysiology, we examined the natural history of progression in imaging and cognitive endpoints to define the rate and variability of progression in a prospective RVCL-S cohort. We hypothesized that cerebral blood flow (CBF) and oxygen extraction fraction (OEF), as metrics of cerebral hypoxia-ischemia, would be associated with neurologic disease progression. We performed sequential brain MRI and a cognitive battery in a prospective RVCL-S cohort. Arterial spin labeling and asymmetric spin echo quantified CBF and OEF in normal-appearing white matter (WM), respectively. Three neuroimaging endpoints of cSVD included the following: log-transformed, normalized fluid-attenuated inversion recovery WM hyperintensity (WMH) volume; WM microstructure using mean diffusivity; and normalized WM volume. Five cognitive and motor endpoints included Digit Symbol Substitution Test (DSST), category fluency, free recall, Montreal Cognitive Assessment (MoCA), and gait speed. Linear mixed-effects models examined age, CBF, and OEF in association with neuroimaging and cognitive progression. Twenty-five participants, aged 23-68 years (median 47 years, 56% female), underwent 151 scans over a median (25th, 75th) of 2.2 (1.8, 4.4) years. All neuroimaging and cognitive endpoints progressed over time, except for MoCA. Of neuroimaging endpoints, WMH volume demonstrated the largest rate of change (+31.3%/year, 95% CI 20.8%-42.3%). Of cognitive endpoints, DSST, a metric of processing speed, showed the steepest decline (-13.1 T-score points/decade, 95% CI -21.2 to -5.32), followed by free recall and category fluency (-5 [-7.9 to -2.4] and -4.1 [-7.2 to -1.2] T-score points per decade, respectively). The age at first brain lesion was estimated to be 30.6 (23.8, 35.8) years, modeled from individual WMH volume trajectories. In multivariable analysis, OEF, but not CBF, was independently associated with WMH growth (β = 3.73, 95% CI 0.63-6.83,  Elevated OEF in at-risk WM was associated with progression in WMH and impairment in WM microstructure, suggesting a role for tissue hypoxia-ischemia in underlying RVCL-S pathophysiology. Cerebral OEF holds promise as a predictive biomarker to risk-stratify patients with RVCL-S and other forms of cSVD.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Mar-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41719494/",
      "summary_ja": "背景：RVCL-Sは単一遺伝子による加齢関連の脳小血管病（cSVD）で、血管性認知症や視力障害、早期死亡を引き起こすが、その病態生理は不明な点が多い。  \n方法：前向きコホートのRVCL-S患者25名（23～68歳）を対象に、脳MRIと認知機能検査を複数回実施。動脈スピンラベリングと非対称スピンエコー法で脳血流（CBF）と酸素抽出率（OEF）を測定し、白質病変量（WMH）、白質微細構造、白質体積の3つの画像指標と、5つの認知・運動指標の進行を線形混合モデルで解析した。  \n結果：全指標は経時的に悪化し、特にWMH量は年率31.3%増加、認知機能では処理速度を示すDSSTが最も急激に低下した。初回脳病変発症年齢は約30歳と推定。多変量解析でOEFはWMH増加と独立して関連し、CBFは関連しなかった。  \n結論：リスクのある白質領域でのOEF上昇は組織の低酸素虚血を反映し、RVCL-Sの病態進行に関与する可能性が高い。脳のOEFはRVCL-Sや他のcSVD患者のリスク層別化に有用なバイオマーカーとなり得る。",
      "summary_short_ja": "RVCL-Sは単一遺伝子による加齢性脳小血管病で、血管性認知症や視力低下を引き起こす。本研究は前向きコホートで脳MRIと認知機能検査を用い、病態進行を評価した。白質病変量は年率31.3%増加し、認知機能では処理速度が最も著しく低下した。酸素抽出率（OEF）が白質病変の進行と関連し、組織の低酸素虚血が病態に関与することを示唆。OEFはRVCL-Sや他の脳小血管病の進行予測バイオマーカーとして有望である。",
      "disease": "dementia",
      "section": "imaging"
    },
    {
      "source": "pubmed",
      "pmid": "41712884",
      "doi": "10.1212/WNL.0000000000214655",
      "title": "Contrast-Associated Acute Kidney Injury After Thrombectomy for Ischemic Stroke: Prognostic Impact and CAN-REST Predictive Score.",
      "abstract": "Contrast-associated acute kidney injury (CA-AKI) is a potentially preventable complication after exposure to iodinated contrast media. In patients undergoing endovascular thrombectomy (EVT) for acute ischemic stroke (AIS), the incidence and clinical impact are poorly characterized, and no validated prediction tool is currently available. The aim of this study was to assess the incidence and prognostic significance of CA-AKI in EVT-treated patients with AIS and to develop and validate a predictive score. A retrospective, multicenter cohort study was conducted involving EVT-treated patients across 73 centers in 16 countries (January-December 2023). Inclusion criteria were age ≥18 years, absence of dialysis, availability of preprocedural and 48-hour postprocedural creatinine levels, and available 90-day follow-up (modified Rankin Scale [mRS] score). The primary outcome was CA-AKI, defined by KDIGO (Kidney Disease: Improving Global Outcomes criteria;creatinine increase ≥0.3 mg/dL or ≥1.5 times baseline, within 48 hours). Secondary outcomes were (1) in-hospital mortality, (2) 90-day mRS score, and (3) 90-day severe disability or death (mRS score >3). Logistic models assessing associations with outcomes accounted for within-center clustering by applying robust standard errors. CA-AKI prediction models were developed across imputed data sets using univariable selection ( Among 6,638 patients (median age 74 years; 48.7% male), CA-AKI occurred in 326 (4.9%) and was independently associated with in-hospital mortality (adjusted odds ratio [aOR] 2.269; 95% CI 1.615-3.190), higher 90-day mRS scores (adjusted common odds ratio 1.584; 95% CI 1.110-2.258), and 90-day severe disability or death (aOR 1.530; 95% CI 1.057-2.216). A preprocedural risk model including 12 routine clinical variables-sex, ethnicity, arterial hypertension, dyslipidemia, chronic kidney disease, antiplatelet therapy, NIH Stroke Scale score at admission, serum glucose, estimated glomerular filtration rate, hemoglobin, mean arterial pressure, and IV thrombolysis-demonstrated acceptable discrimination (area under the receiver operating characteristic curve 0.710 [95% CI 0.682-0.738]; precision-recall area under the curve 0.13 [95% CI 0.10-0.16]), good calibration (slope 0.870 [95% CI 0.759-0.928]), good overall performance (Brier score 0.045 [95% CI 0.042-0.049]). A second model that included EVT-related variables (e.g., contrast volume) showed similar performances. In this large, international cohort, CA-AKI occurred in approximately 1 in 20 EVT-treated patients with AIS and was independently associated with poor outcomes. A simple preprocedural risk score enables early identification of high-risk individuals and may support preventive strategies.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Mar-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41712884/",
      "summary_ja": "背景：急性虚血性脳卒中（AIS）に対する血栓回収術（EVT）後のヨード造影剤関連急性腎障害（CA-AKI）は予防可能な合併症であるが、その発生率や臨床的影響は不明瞭であり、予測ツールも存在しない。  \n方法：16か国73施設のEVT施行患者6,638例（中央値年齢74歳）を対象に、術前および術後48時間のクレアチニン値と90日後の修正Rankinスケール（mRS）を用いてCA-AKIの発生率と予後への影響を後ろ向きに解析。CA-AKIはKDIGO基準で定義。予測モデルは12の臨床変数を用いて構築・検証した。  \n結果：CA-AKIは4.9%に発生し、入院中死亡（調整オッズ比2.269）、90日後の重度障害または死亡（mRS>3、aOR1.530）と有意に関連。予測モデルはROC曲線下面積0.710で良好な識別能を示した。造影剤量を含むモデルでも同様の性能を示した。  \n結論：AISに対するEVT後のCA-AKIは約5%に発生し、予後不良と独立して関連する。簡便な術前リスクスコアにより高リスク患者の早期同定が可能であり、予防策の実施に有用である。",
      "summary_short_ja": "虚血性脳卒中に対する血栓回収術後の造影剤関連急性腎障害（CA-AKI）は約5%に発生し、入院中死亡率や90日後の重度障害・死亡と独立して関連した。本研究は16か国73施設の6638例を対象に、12の臨床指標を用いたCA-AKI予測スコア「CAN-REST」を開発・検証し、良好な予測性能を示した。早期リスク評価により予防策の検討が期待される。",
      "disease": "stroke",
      "section": "prognosis"
    }
  ]
}